Recent chemotherapy reduces the sensitivity of [18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases Journal Article

Authors: Akhurst, T.; Kates, T. J.; Mazumdar, M.; Yeung, H.; Riedel, E. R.; Burt, B. M.; Blumgart, L.; Jarnagin, W.; Larson, S. M.; Fong, Y.
Article Title: Recent chemotherapy reduces the sensitivity of [18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases
Abstract: Purpose: [18F]2-fluoro-2-deoxyglucose (FDG) -positron emission tomography (PET) has become a useful tool in the assessment of patients with colorectal cancer. Patients often undergo chemotherapy as treatment for primary or metastatic colorectal malignancy. Because cytotoxic chemotherapy may decrease the cellular metabolic activity of tumor, we assessed the effects of chemotherapy on PET imaging. Patients and Methods: This is a prospective study examining detection of hepatic colorectal metastases by FDG-PET as related to use of chemotherapy. Pathologic analysis of the liver resection specimens was used as gold standard. Results: There was significantly decreased tumor FDG uptake (as measured by the maximal standardized uptake value) in patients treated preoperatively with chemotherapy, resulting in less efficient detection of cancerous lesions. One biologic basis of this change in accuracy of PET was a significant decrease in the activity of the key glycolytic enzyme hexokinase in tumors from patients treated with chemotherapy. Conclusion: These results indicate that FDG-PET scanning should be interpreted in the context of concurrent cytotoxic therapy. FDG-PET scanning results may also be useful in assessment of response to such cytotoxic therapies. © 2005 by American Society of Clinical Oncology.
Keywords: adult; cancer chemotherapy; clinical article; controlled study; treatment outcome; treatment response; aged; middle aged; histopathology; fluorouracil; multimodality cancer therapy; liver neoplasms; adjuvant therapy; comparative study; combined modality therapy; cancer staging; positron emission tomography; methodology; cancer diagnosis; diagnostic accuracy; laboratory diagnosis; prospective study; sensitivity and specificity; prospective studies; colorectal cancer; reproducibility; reproducibility of results; metastasis; antimetabolites, antineoplastic; tumor volume; drug effect; pathology; enzyme activity; colorectal neoplasms; standard; liver metastasis; liver; diagnostic agent; evaluation; colorectal tumor; liver tumor; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; scintiscanning; liver resection; multivariate analysis; abdominal surgery; regression analysis; antineoplastic antimetabolite; radiodiagnosis; digestive system surgical procedures; hexokinase; contrast sensitivity
Journal Title: Journal of Clinical Oncology
Volume: 23
Issue: 34
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2005-12-01
Start Page: 8713
End Page: 8716
Language: English
DOI: 10.1200/jco.2005.04.4222
PUBMED: 16314631
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 49" - "Export Date: 24 October 2012" - "CODEN: JCOND" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Leslie H Blumgart
    340 Blumgart
  2. Madhu Mazumdar
    120 Mazumdar
  3. Henry W D Yeung
    127 Yeung
  4. Bryan M Burt
    18 Burt
  5. William R Jarnagin
    583 Jarnagin
  6. Yuman Fong
    741 Fong
  7. Timothy J Akhurst
    134 Akhurst
  8. Steven M Larson
    762 Larson
  9. Tara J Kates
    3 Kates